Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 14/20 | 0.78 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1971777 | 0.88 | GRM4 (1.00) | GRM4GRM1CYP2C9 | |
| SCHEMBL12037581 | 0.85 | GRM4 (0.55) | GRM4GRM1 | |
| SCHEMBL1897912 | 0.83 | GRM4 (1.00) | GRM4GRM1CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL12037587 | 0.83 | GRM4 (0.85) | GRM4GRM1CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL1897904 | 0.81 | GRM4 (0.71) | GRM4GRM1CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL1972220 | 0.80 | GRM4 (0.82) | GRM4GRM1CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL1975043 | 0.80 | GRM4 (1.00) | GRM4GRM1CYP2C9CYP1A2 | |
| SCHEMBL1968923 | 0.80 | GRM4 (1.00) | GRM4GRM1CYP2C9 | |
| SCHEMBL1898009 | 0.78 | GRM4 (0.80) | GRM4GRM1CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL1513878 | 0.78 | GRM4 (0.72) | GRM4GRM1CYP2C9CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759377-B2 | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759377-B2 | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759377-B2 | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2014-06-24 | — | — | US | disclosed |
| US-20110124663-A1 | SUBSTITUTED DIOXOPIPERIDINES AND DIOXOPYRROLIDINES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2011-05-26 | — | — | US | disclosed |
| US-20110124663-A1 | SUBSTITUTED DIOXOPIPERIDINES AND DIOXOPYRROLIDINES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2011-05-26 | — | — | US | disclosed |
| US-20110124663-A1 | SUBSTITUTED DIOXOPIPERIDINES AND DIOXOPYRROLIDINES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124663-A1 | SUBSTITUTED DIOXOPIPERIDINES AND DIOXOPYRROLIDINES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRM4, GRIA4, GRIK4 | GRM4 1/4885GRM1 5/4885CYP2C9 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.